CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
A phase 1/2 trial of Ibrutinib in brain and spinal cord tumours, run by Curis, Inc., now recruiting.
Overview
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) is a phase 1/2 interventional study registered as NCT03328078 by Curis, Inc., with 152 participants planned, started 2017-12-28 and due to reach its primary completion in 2026-08. Interventions recorded: Emavusertib and Ibrutinib.
Similar pages
not linked directly; found by shared links- TrialA Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Shares Emavusertib, Curis and the tag pipeline.
- TrialStudy of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialPost-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Shares Brain and spinal cord tumours (all types) and the tag pipeline.